Clinical study of thalidomide combined with dexamethasone for the treatment of elderly patients with newly diagnosed multiple myeloma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4777-4781

  Chen, Hai Fei ^a,b   Li, Zheng Yang ^a   Tang, Jie Qing ^a   Shen, Hong Shi ^a   Cui, Qing Ya ^a   Ren, Yong Ya ^a   Qin, Long Mei ^a   Jin, Ling Juan ^a   zhu, ing Jing ^a   Wang, Jing ^a   Ding, Jie ^a   Wang, Ke Yuan ^a   Yu, Zi Qiang ^b   Wang, Zhao Yue ^b   Wu, Tian Qin ^a  

^a PLA 100th Hospital   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Chemotherapy; Dose; Efficacy; Multiple myeloma; Thalidomide; Toxicity

Indexed keywords

EID: 84874004260     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4777     Document Type: Article

References (24)

1. Alexanian R, Haut A, Khan AU, et al (1969). Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA, 208, 1680-5.
2. Attal M, Harousseau JL, Stoppa AM, et al (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med, 335, 91-7.
3. Bladé J, Cibeira MT, Rosiñol L(2005). Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol, 44, 440-8.
4. Cavallo F, Boccadoro M, Palumbo A (2007). Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther Clin Risk Manag, 3, 543-52.
5. Child JA, Morgan GJ, Davies FE, et al(2003). High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl JMed, 348, 1875-83.
6. Cohen HJ, Crawford J, Rao MK, et al (1998). Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med, 104, 439-44.
7. Durie BG, Harousseau JL, Miguel JS, et al (2006). International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-73.
8. Fukushima T, Nakamura T, Iwao H, et al (2011). Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res, 31, 2297-302.
9. Gay F, Hayman SR, Lacy MQ, et a l(2010). Lenalidomide plus dexamethasone versus Thal plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood, 115, 343-50.
10. Gay F, Palumbo A (2011). Management of older patients with multiple myeloma. Blood Rev, 25, 65-73.
11. Gay F, Vincent Rajkumar S, Falco P, et al (2010). Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. Eur J Haematol, 85, 200-8.
12. Harousseau JL(2002). High-dose therapy in multiple myeloma. Ann Oncol, 13, S49-54.
13. Hulin C, Facon T, Rodon T, et al (2007). Melphalan-Prednisone- Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with Multiple Melphalan-Prednisone (MP) in a Randomized, Double- Blind, Placebo-Controlled Trial, IFM 01/01. Blood, 110, 31a [Abstract 75].
14. International Myeloma Working Group (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol, 121, 749-57.
15. Kastritis E, Dimopoulos MA (2007). Thalidomide in the treatment of multiple myeloma. Best Pract Res Clin Haematol, 20, 681-99.
16. Kyle RA, Rajkumar SV(2004). Multiple myeloma. N Engl J Med, 351, 1860-73.
17. Moreau P, Avet-Loiseau H, Facon T, et al (2011). Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood, 118, 5752-8.
18. Palumbo A, Facon T, Sonneveld P, et al (2008). Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 111, 3968-77.
19. Rajkumar SV, Blood E, Vesole D, et al (2006). Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed myeloma: a clinial trial coordinated by the Eastern Cooperative Group. J Clin Oncol, 24, 431-6.
20. Rajkumar SV, Hayman S, Gertz MA, et al (2002). Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol, 20, 4319-23.
21. Rajkumar SV, Rosinol L, Hussein M, et al (2008). Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol, 26, 2171-7.
22. Saad AA, Sharma M, Higa GM (2009).Treatment of multiple myeloma in the targeted therapy era. Ann Pharmacother, 43, 329-38.
23. San Miguel JF, Blade Creixenti J, Garcia-Sanz R (1999). Treatment of multiple myeloma. Haematologica, 84, 36-58
24. Yakoub-Agha I, Mary JY, Hulin C, et al (2011). Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. Eur J Haematol, 88, 249-59.